THCv & Weightloss
THCv, or tetrahydrocannabivarin, is a compound in hemp that offers a unique array of effects and medical benefits that sets it apart from other compounds. THC and THCv are almost identical in structure but there are stark differences which make THCv stand out. THCv is only psychoactive in extremely high doses. At high doses in potent strains, THCv will produce effects that are generally stimulating and promote mental clarity. They are also fast-acting and fast-dissipating. This is the reason THCv is referred to as the sports car of cannabinoids.
Is THCv legal?
THCv is not scheduled at the federal level in America, nor is it scheduled by the Convention on Psychotropic Substances. THCv is federally legal as long as it’s extracted from hemp plants that contain less than 0.3% THC. At a state level, THCv is also permitted in all cannabis strains where medical and/or adult use is legal.
Effects of THCv:
THCv activates CB1 receptors but blocks CB2 receptors and therefore may be an appetite suppressant. This may be good for consumers focused on weight loss. THC on the other hand has a reputation for enhancing appetite to create what is sometimes called ‘the munchies’. THCv should be avoided by patients being treated for appetite loss or anorexia.
THCv may also have been shown to regulate blood sugar levels and reduce insulin resistance. The medical community is very interested in the appetite suppressing qualities of THCv. This natural and non-addictive product which lacks the side effects of traditional pharmaceutical therapies, may be of benefit to consumers suffering from conditions like obesity and Type 2 diabetes.
THCv may also stimulate bone growth. Because it may promote the growth of new bone cells, it is being looked at for osteoporosis and other bone-related conditions. For the same reasons that it is helpful for Alzheimer’s disease, this special compound shows promise for alleviating the symptoms of and delaying the neurodegeneration associated with Parkinson’s disease. THCv may also prevent and relieve panic attacks in patients suffering from PTSD.
From the Journal of Cannabinoid Medicine: (regarding THCv)
"In complete contrast to Delta-9 THC, consumption of THCv actually suppresses appetite. The CB1 receptor controls eating behavior and appetite regulation. Preclinical studies have shown that treatment with a CB1 antagonist (blocker) , as well as pure THCv, suppresses food intake and causes weight loss. THCv blocks the CB1 receptor at low doses and so may be effective as an anti-obesity treatment.
THCv has additionally been shown to improve fasting plasma glucose and glucose tolerance, as well as insulin sensitivity. Preclinical models of obesity showed these effects appear to be mediated through increased energy expenditure. And while these results are indeed promising, they are not confined to animal studies alone, similar results have also been found in humans."
As with other minor cannabinoids, a growing body of research suggests that a full spectrum of cannabinoids may have a more beneficial effect than only a few. Referring again, to the entourage effect playing an important role in the synergistic mechanism and corresponding therapeutic properties of cannabinoids.
The information contained in this article is for educational and informational purposes only and is not intended as health or medical advice. Always consult a physician or other qualified health provider regarding any questions you may have about a medical condition or health objectives.
Riedel, G., Fadda, P., McKillop-Smith, S., et al., "Synthetic and Plant-derived Cannabinoid Receptor Antagonists Show Hypophagic Properties in Fasted and Non-fasted Mice", Br J Pharmacol, 2009, Volume 156, pg. 1154-1166.
Ravinet, T.C., Arnone, M., Delgorge, C., et al., "Anti-obesity Effect of SR141716, a CB1 Receptor Antagonist, in Diet-induced Obese Mice", Am J Physiol Regul Integr Comp Physiol, 2003, Volume 284, pg. R345-353.
Wargent, E.T., Zaibi, M.S., Silvestri, C., et al., "The cannabinoid Δ9-tetrahydrocannabivarin (THCV) Ameliorates Insulin Sensitivity in Two Mouse Models of Obesity", Nutr Diabetes, 2013, Volume 3, pg. e68.